Prot #MK-3475-361: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma

Project: Research project

Project Details

StatusActive
Effective start/end date2/17/172/28/22

Funding

  • DrugDev Inc. (Prot #MK-3475-361)
  • Merck Sharp & Dohme Corporation (Prot #MK-3475-361)